Ask the Expert: Clear up confusion about 5010 and drug claims

Why This Topic Matters

Drug claims were affected by claim-format changes that required practices to understand how payer reporting fields map to drug identifiers and related billing elements. Readers who submit these claims need to know which guidance sources and claim areas the article discusses so they can judge whether the full premium content is relevant to their workflow.

Article Sections

1. The National Drug Code (NDC): How do we report the National Drug Code (NDC) on 5010?

   Introduces the reporting question for drug identifiers on the 5010 claim format and cites payer and CMS-related guidance. The section also references formatting considerations tied to the transition period.

2. Compound drugs

   Addresses questions about reporting compound-drug claims under 5010 and discusses the general structure of linked service and drug entries. The section references CMS guidance on how multiple ingredients are handled at a high level.

3. Epoetin

   Covers a drug-specific billing question involving services with more than one dose component or identifier. The section explains that the topic is treated in relation to the broader compound-drug discussion.

4. Oral anti-cancer drugs

   Discusses claim-format questions for oral oncology drugs submitted to regional DME MACs when standard drug coding situations are involved. The section also references CMS guidance and related TR3 sections.